43
Participants
Start Date
November 30, 2005
Primary Completion Date
August 31, 2010
Study Completion Date
August 31, 2010
bevacizumab [Avastin]
5 mg/kg intravenously every 2 weeks, 4 cycles
capecitabine [Xeloda]
825 mg/m2 twice daily orally, 38 days
Radiation therapy
Total dose of 45 Gy over 38 days
Mesorectal excision
6-8 weeks after completion of neoadjuvant treatment
bevacizumab [Avastin]
Post-surgery adjuvant treatment at the discretion of the investigator: 5 mg/kg iv every 2 weeks for at least 6 months
5-fluorouracil
Post-surgery adjuvant therapy: bolus of 400mg/m2 iv plus iv infusion of 600 mg/m2 on Days 1 and 2 of each 2-week cycle for 6 months
leucovorin
Post-surgery adjuvant treatment: 100 mg/m2 iv on Days 1 and 2 of each 2-week cycle for 6 months
Cuneo
Genova
Bologna
Siena
Pisa
Ancona
Napoli
Paola
Roma
Hoffmann-La Roche
INDUSTRY